diabetestalk.net

Eli Lilly Insulin Pen

Eli Lilly India Launches Humalog 200u/ml Kwikpen

Eli Lilly India Launches Humalog 200u/ml Kwikpen

Eli Lilly India launches Humalog 200U/mL KwikPen Eli Lilly India launches Humalog 200U/mL KwikPen The product contains 200 U/mL rapid acting insulin, delivers the same benefits of Humalog 100U/mL in half the volume and operates with a much smoother glide force New Delhi: Eli Lilly and Company (India) has announced the launch of Humalog 200U/mL KwikPen(insulin lispro 200U/mL), a pre-filled pen containing a concentrated formulation of Lillys rapid-acting insulin Humalog (insulin lispro). Over time, some patients may require dosage increase for improved glycemic control. This also leads to increase in number of pens being used. Humalog 200 U/mL KwikPenoffers physicians an alternative that allows patients to inject 50% less insulin volume. Often the transition to a more intensified mealtime insulin therapy is difficult for patients. Humalog 200 U/mL KwikPenis another option that may help make mealtime insulin therapy more convenient. Humalog 200U/mL KwikPen contains concentrated 200U/mL rapid-acting insulin and delivers the same units of insulin in half the volume as 100U/mL mealtime insulin pens. It holds twice as many insulin units, hence it lasts longer and allow fewer pen changes every month. With no dose conversions required it can be dialed in one-unit increments to a maximum of 60 units per injection#. Patients may require dosage increase over time for better glycemic control. Humalog 200U/mL KwikPenTM provides physicians a new prescription option for their patients. Fewer pen changes per month may help people who require higher daily doses of mealtime insulin making it a convenient option for patients who lead busy lives, said MrEdgard Olaizola, Managing Director, Eli Lilly and Company (India),Lilly is committed to bringing innovative products to India. Since 1923, Continue reading >>

Lilly Developing Smart Pens And Automated Insulin Delivery With A Pump

Lilly Developing Smart Pens And Automated Insulin Delivery With A Pump

By Jeemin Kwon, Brian Levine, and Adam Brown First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company During a time of fast-paced innovation and competition in the world of diabetes, Lilly has joined the race to offer tech-enabled, smarter methods of insulin delivery to people with diabetes. In two to three years, Lilly, a major insulin player, plans to launch two systems: Automated insulin delivery (AID) with Lilly’s own custom disk-shaped pump, CGM, and a hybrid closed loop control algorithm; and Smart insulin pens with a dosing decision (“titration”) support app. Lilly has been developing both products for two years, and the first trials are expected to begin next month. Dexcom’s CGM will be used in both, per an agreement announced in tandem with this news. All three major insulin companies – Lilly, Novo Nordisk, and Sanofi – are investing in digital health and connected delivery devices, though this represents the largest commitment yet. Lilly will bring all the components together for smarter insulin delivery (both pump and injection), submit them to the FDA, and commercialize both systems. Bigfoot Biomedical is currently the only other company pursuing both injection- and pump-based automated delivery of insulin. Read below for more details! Lilly’s AID System – A New Disk-Shaped Pump Lilly’s AID system will use its own custom pump designed by Dean Kamen and the team at Deka Research and Development Corp (inventors of the Segway). The tubed pump is “a white disk about the size of a shoe-polish tin” and holds three days of insulin. It has an infusion set with tubing, but in a new approach, is small enough to be worn directly on the body (like a patch pump) o Continue reading >>

Advances In Insulin Pen Technologies: Lessons Learned During The Development Of Humapen Memoir, An Insulin Pen With A Memory Feature

Advances In Insulin Pen Technologies: Lessons Learned During The Development Of Humapen Memoir, An Insulin Pen With A Memory Feature

Lessons Learned during the Development of HumaPen Memoir, an Insulin Pen with a Memory Feature 1Delivery Device Research and Development, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 2Diabetes/Endocrine Medical, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 3Medical Device Solutions, Battelle Memorial Institute, Columbus, Ohio Correspondence to: Stuart D. Breslin, Delivery Device Research and Development, Lilly Corporate Center, Indianapolis, IN 46285; email address [email protected]_trauts_nilserb Disclosures: Stuart Breslin and Debra Ignaut are shareholders and employees of Eli Lilly and Company, which manufactures the HumaPen Memoir insulin pen. Douglas Boyd is an employee of Battelle Memorial Institute, which codeveloped the HumaPen Memoir insulin pen with Eli Lilly. Copyright 2010 Diabetes Technology Society This article has been cited by other articles in PMC. Insulin pens are developed to address specific needs of diabetes patients for their pens, such as ease of use, portability, and discreetness. Like many consumer-based products, the development of insulin pens can pose significant challenges to the development team in that they must balance substantial accuracy requirements with aesthetic desires. The HumaPen Memoir team learned valuable lessons throughout the development process that may be worth highlighting. A keen understanding of the unmet needs of the patient population and a skillfully planned product generation map are critical to successful device development. A development team must decide whether to use a Quality Functional Deployment or system engineering-based development plan and, additionally, recognize where proof of concept ends and product development begins to maintain a strict timeline for the proj Continue reading >>

Welcome To The Humalog® Family Of Insulins.

Welcome To The Humalog® Family Of Insulins.

Humalog® is used to treat people with diabetes for the control of blood sugar. Humalog® Mix75/25™(75% insulin lispro protamine suspension and 25% insulin lispro injection) and Humalog® Mix50/50™(50% insulin lispro protamine suspension and 50% insulin lispro injection) are used to treat adults with diabetes for the control of high blood sugar. Do not share your Humalog, Humalog Junior, Humalog Mix75/25, or Humalog Mix50/50 KwikPens, cartridges, reusable pen compatible with Lilly 3 mL cartridges, or syringes with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them. The Humalog contained in the Humalog U-200 KwikPen should ONLY be injected with the Humalog U-200 KwikPen. Do NOT withdraw Humalog U-200 from the pen using a syringe. It could result in an overdose causing severe low blood sugar which may put your life in danger. Do not change the insulin you use without talking to your healthcare provider. Changes may make you more likely to experience low or high blood sugar. Changes should be made cautiously under the supervision of your healthcare provider. When used in a pump, do not mix or dilute Humalog U-100 with any other insulin or liquid. Do NOT use Humalog U-200, Humalog Mix75/25 or Humalog Mix50/50 in a pump. These insulins start working faster than other insulins that contain regular human insulin. You should take Humalog within fifteen minutes before eating or right after eating a meal. You should take Humalog Mix75/25 and Humalog Mix50/50 within fifteen minutes before eating. Do not use Humalog Mix75/25 or Humalog Mix50/50 if they have solid particles or clumps in them. Humalog Mix75/25 and Humalog Mix50/50 should be mixed carefully before each use and should be cloudy or mi Continue reading >>

Maude Adverse Event Report: Eli Lilly And Co. Humapen Luxura Insulin Pen

Maude Adverse Event Report: Eli Lilly And Co. Humapen Luxura Insulin Pen

MAUDE Adverse Event Report: ELI LILLY AND CO. HUMAPEN LUXURA INSULIN PEN (b)(6). Dear fda, i am complaining about a humalog insulin delivery pen luxura made by eli lilly and the subsequent, so called, customer service. The pen broke. The pen has a screw device that turns and depresses a plunger below an insulin cartridge vial. The flat top of this screw came/broke off. I called the eli lilly company to ask if it -the flat top- could be placed back and fixed easily. The person at eli lilly to whom i spoke told me it was broken and the screw shaft and flat top were all made from one single piece of metal. My new replacement pen already a wobbly flat top part of the screw device which leads me to think that the screw shaft and flat top are not one metal piece, but are joined together in someway and not very durable. This humalog luxura pen seems to have a flawed design and should be re-evaluated by the fda. Eli lilly has sent me an envelope in which to return the original pen and made several phone calls to my home asking for the broken pen. I am keeping this pen until i am satisfied that my complaint and suggestions to you and to eli lilly have been noted. I would be willing to send the luxura pen to the fda for re-evaluation if necessary. Eli lilly customer service - the customer service person at eli lilly asked several personal health related questions before she would address the issue of the broken pen. If i have product malfunction, e. G. , a car, an appliance or computer i am not asked a variety of personal questions which have no real relationship to the broken part of the product. I am not asked for my unpublished phone number on the pretext that the company may wish to contact me on that line and also if i am assured the broken item will be replaced immediately Continue reading >>

Eli Lilly Humalog Manufacturing Facility, Carolina

Eli Lilly Humalog Manufacturing Facility, Carolina

Eli Lilly began production of the insulin product Humalog at its new bulk manufacturing facility in Carolina, Puerto Rico, in mid-2005. Scanning electron micrograph of E. coli as used for recombinant DNA techniques. Pro-insulin and human insulin, showing where the trypsin cleavage occurs. In April 2001 Eli Lilly announced it was constructing a new biotech bulk manufacturing facility in Carolina, Puerto Rico. Construction started in July 2002 and, following validation and commissioning, the plant was in production by mid-2006. This project was part of an overall $1bn investment into the company’s facilities in Puerto Rico, which was completed in August 2006. The 300,000ft² facility produces the rapid-acting insulin product Humalog, dispensed from the KwikPen (MirioPen), which is manufactured in Indianapolis. The production of this requires the use of recombinant DNA technology via insulin lispro [rDNA origin] injection. KwikPens became available for Humalog, Humalog Mix75/25 and Humalog Mix50/50 in February 2008. KwikPen is the third new insulin pen launched since 2007 to improve the daily management of diabetes. Previous models include the HumaPen MEMOIR, the world’s first digital insulin pen with memory; and HumaPen LUXURA HD, a reusable pen for patients who need insulin dosing in smaller increments. In February 2010, the plant was issued a warning letter by the US Food and Drug Administration (FDA) for deviations in cGMP API production. The FDA cited deviations during an inspection conducted in 2009. Deviations were found in 24 batches of Lyspro Insulin Zinc Crystals, the API in Humalog, released between December 2007 and March 2008. Production of the original Humalog pre-filled pens including the Humalog Mix75/25 and the Humalog Mix50/50 was discontinued Continue reading >>

Global Diabetes Disposable Insulin Pen Market 2011-2022 Featuring Novo Nordisk, Eli Lilly And Sanofi

Global Diabetes Disposable Insulin Pen Market 2011-2022 Featuring Novo Nordisk, Eli Lilly And Sanofi

Global Diabetes Disposable Insulin Pen Market 2011-2022 Featuring Novo Nordisk, Eli Lilly and Sanofi Research and Markets has announced the addition of the "Global Diabetes Disposable Insulin Pen Market Report: Country Outlook, Analysis, Size, Share and Forecast 2017 - 2022" report to their offering. Diabetes Disposable Insulin Pen Market is likely to reach more than US$ 9 Billion across the ten major markets (10MM) of the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China, India and Brazil by the year end of 2022. Market growth can be attributed to factors such as growing diabetes patient population, high adoption rate, user-friendly design, rising popularity among consumers, help avoid over/under-dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices United States became the world's biggest market of disposable insulin pen. United States market for disposable insulin pen is expected to reach more than US$ 2.5 Billion by the end of 2022. Japan will be the second-biggest market for disposable insulin pen by 2022. Germany is expected to be third biggest disposable insulin pen market being followed by Spain by the end of 2022. The report concludes with the profiles of major players in the insulin pen market such as Novo Nordisk, Eli Lilly and Sanofi. The major market players are evaluated on various parameters such as company overview, product outlook and latest development and trends of the insulin pen market. 2. Prefilled (Disposable) Insulin Pen Market Environment & Trend (2011 - 2022) 3. Prefilled (Disposable) Insulin Pen Market Share Analysis (2011 - 2022) 4. Prefilled (Disposable) Insulin Pen Market Drivers and Barriers 5. Prefilled (Disposable) Continue reading >>

About My Insulin Pen

About My Insulin Pen

Do you have questions about your insulin injection pen? Get the answers you need by watching the following videos: There are two main types of insulin pens, Reusable and Disposable. How to Store and Travel with Your Insulin Pen Kwikpen Insulin Cartridge Delivery Device User Manual Kwikpen Insulin Delivery Device User Manual You are leaving this site. Lilly is not responsible for the content or Privacy Policy of the site you are about to visit. We encourage you to read the Privacy Policy of every site you visit. 2017 Eli Lilly and Company. All rights reserved. Use of this website constitutes acceptance of our Terms of Use and Privacy Policy . Access our Sitemap . ZADBT00624 2017 Eli Lilly and Company. All rights reserved. Use of this website constitutes acceptance of our Terms of Use and Privacy Policy . Access our Sitemap . Please confirm that you are prescribed a Lilly insulin product. Continue reading >>

Bd Introduces Specialized Syringe For Eli Lilly's Highly Concentrated Insulin

Bd Introduces Specialized Syringe For Eli Lilly's Highly Concentrated Insulin

BD Introduces Specialized Syringe For Eli Lilly's Highly Concentrated Insulin Becton, Dickinson and Company (BD) has launched a new syringe designed specifically for diabetic patients taking Humulin R U-500, concentrated insulin developed and manufactured by Eli Lilly. By using a specialized syringe, patients and clinicians can avoid the dosing errors associated with traditional insulin syringes. Some diabetic patients become resistant to insulin therapy and require higher doses 200 units per day to manage their disease correctly. Eli Lillys Humulin R U-500 contains five times more insulin per milliliter than traditional U-100 insulin, and has been available since 1994. Since Humulin R U-500s introduction, doctors and patients have had to portion out converted dosages into syringes intended for insulin at lower concentrations, and this manual conversion must be managed carefully to avoid serious side effects. According to the products labeling , the therapy carries significant risk of hyper- or hypoglycemia if dosages are miscalculated. FDA approved BDs specialized syringe in July and indicated in its announcement that the device should be co-prescribed with vials of U-500 insulin. The new syringe comes with the shortest insulin syringe needle on the market, measuring six millimeters by 31-guage, which helps reduce the risk of intramuscular injection. The syringe is clearly marked so that patients can distinguish between new syringes and traditional products intended for U-100 insulin. People with diabetes and severe insulin resistance who have become poorly responsive to the effects of insulin may require much higher insulin doses to help keep their blood sugar levels on target, explained Jeffrey Jackson, from U.S. Medical Affairs for Lilly Diabetes, in a press releas Continue reading >>

Eli Lilly New Zealand

Eli Lilly New Zealand

This website is intended for New Zealand residents over the age of 18. The information you are about to be referred to is from a global Lilly website or third party controlled website and may not comply with New Zealand regulatory requirements. Please refer to the Consumer Medicine Information (CMI) for products to fully understand the terms of registration of products in New Zealand. Healthcare professionals may also refer to the Product Data Sheet. Further information relevant to the New Zealand environment is available by contacting Eli Lilly New Zealand or via the relevant section of our product page . The intention of providing this link is for information purposes and is not intended as advice. Any information provided by this source should be discussed with a healthcare professional and does not replace their advice. Eli Lilly New Zealand does not control the website you are about to be referred to and is not responsible for the terms of use and the privacy policy of that site. We encourage you to read the terms of use and the privacy policy of every website you visit. Continue reading >>

News: Lilly Developing Its Own Insulin Pump And Smart Pen Device

News: Lilly Developing Its Own Insulin Pump And Smart Pen Device

In the next two or three years, Eli Lilly wants to become more than just an insulin company. The Indianapolis-based Pharma giant has been quietly working on diabetes technology behind the scenes since 2015, and just recently publicly disclosed that it's working specifically on a tubed insulin pump with infusion set and a smart insulin pen that will deliver insulin, track data, and communicate with the Dexcom CGM for a full mobile health offering. Yup, in mid-November Lilly announced it had signed a development agreement with Dexcom to weave that CGM data into its future connected devices. Two articles from the Wall Street Journal and FierceBiotech expanded on that news by delving into the broader "connected diabetes ecosystem" the company says it's developing. This all comes at a time of a major shift in the D-Tech market, with insulin pump choice evaporating thanks to JnJ Animas being shut down and Roche stopping its sales of insulin pumps, along with uncertainty about Tandem's future. Medtronic remains as the big behemoth in diabetes devices, while OmniPod remains the only patch pump in the USA. Most of these vendors are now looking more at closed loop systems rather than stand-alone insulin pumps. On the CGM side, Dexcom and Medtronic may be facing a new kind of competition from the new Abbott Freestyle Libre, a simpler sort of CGM that requires no fingerstick calibrations. With Lilly publicly putting its name in the ring as a device maker, we may soon be seeing an interesting new dynamic in the market... Lilly's Diabetes Tech Pipeline Here's a snapshot of what we understand is in the works, garnered from a combination of what we've been told directly by Lilly Diabetes and what the WSJ reported: Connected Diabetes Ecosystem: This is the term Lilly's throwing around f Continue reading >>

Insulin

Insulin

Indication BASAGLAR is a long-acting insulin used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. Limitation of Use BASAGLAR is not for treating diabetic ketoacidosis. Important Safety Information Do not take BASAGLAR during episodes of low blood sugar or if you are allergic to insulin glargine or any of the ingredients in BASAGLAR. Do NOT reuse needles or share insulin pens, even if the needle has been changed. Before starting BASAGLAR, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant, or if you are breastfeeding or planning to breastfeed. BASAGLAR should be taken once a day at the same time every day. Test your blood sugar levels while using insulin. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. The most common side effect of insulin, including BASAGLAR, is low blood sugar (hypoglycemia), which may be serious and life threatening. Signs and symptoms may include dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood change, or hunger. Do NOT dilute or mix BASAGLAR with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. BASAGLAR must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection. BASAGLAR may cause serious side effects that can lead to death, such as severe allergic reactions. Get emergency help if you have: Heart fa Continue reading >>

New Eli Lilly Insulin Pen Packs More Punch

New Eli Lilly Insulin Pen Packs More Punch

The same dose with half the liquid volume. That's the claim of a new insulin pen from Eli Lilly and Co. The Indianapolis drugmaker became the first company to get federal approval to sell pre-filled injection pens with a concentrated dose of mealtime insulin. The Food and Drug Administration approved Lilly's KwikPen filled with a concentrated, rapid-acting form of insulin called Humalog, Lilly said. The new pen delivers the same dose in half the liquid volume. That should make it easier for users to carry multiple doses of insulin on trips and to inject it, said Lilly spokeswoman Julie Williams. Liquid insulin, typically injected into the abdomen, can sometimes "bubble up in the abdomen and be uncomfortable," so some users would prefer to be able to inject a smaller amount, Williams said. (Photo: Provided by Eli Lilly and Co.) "It is a big deal for people who need it," she said of the concentrated-dose insulin pen. Pens are an alternative to needles and are increasingly popular among diabetics to inject insulin conveniently and discreetly. Lilly already sells the concentrated dose pen in seven other countries. It was approved for sale in Europe last fall. Rival insulin makers are expected to come out with similar pens holding concentrated doses. "Diabetes is a progressive disease that often requires increased doses of insulin over time to better control a patient's blood sugar levels," Dr. David Kendall, vice president of medical affairs for Lilly Diabetes, said in a statement. The new Humalog KwikPen, he said, "represents a new option for people with diabetes. Fewer pen changes per month may help people who require higher daily doses of mealtime insulin better fit their treatment in their daily lives." Call Star reporter Jeff Swiatek at (317)444-6483. Follow him on Twi Continue reading >>

Designing Pharmaceutical Excellence With Eli Lilly

Designing Pharmaceutical Excellence With Eli Lilly

A decades-long relationship between IDEO and Eli Lilly that has transformed patients' lives and health outcomes Since the time Eli Lilly and IDEO first collaborated in 1990, the partnership has redefined the relationship between patient, health, and treatment. IDEO and Lilly, along with Lilly’s other design, development, and manufacturing partners, have collaborated on more than 250 projects over the last 25 years, taking them from groundbreaking engineering-only design to their evolution as a full-fledged human-centered organization, helping millions of patients in the process. Communication and consistency have been key in maintaining the long-term nature of their partnership. In fact, the relationship has evolved to be more like partners working together than a client and consultant. This not only informs the large-scale projects, but also the smallest details. “We have this kind of consistency, where they feel they can just pick up the phone and say, Can you help us?” said IDEO Design Director Dirk Ahlgrim. “They know we will challenge them, maybe do even more than they asked us to do, because we are more like partners.” This heightened level of communication led to a global research project in which a team of IDEO designers traveled the world to understand how people with diabetes lived with the disease. The results of their findings led to the design of a series of award-winning insulin injection pens like SAVVIO. The new injection pens were personalized to the patient, and crossed over from medical devices to personal devices, completely changing the way patients thought about their condition and their treatment. Lilly and IDEO’s latest collaboration, Trulicity, takes the injection pen as personal device one step further: By ensuring consistent dosage Continue reading >>

Eli Lilly Launches Reusable Insulin Pen - Business Line

Eli Lilly Launches Reusable Insulin Pen - Business Line

Eli Lilly enters branded generics segment Eli Lilly and Company India aims to be in the top-20 list of pharmaceutical companies in the nation by 2020, Eli Lilly India MD Edgard A. Olaizola told Business Line here on Tuesday. The company will be bringing in all its diabetes products to the country, Olaizola said. It has launched a new reusable insulin pen, the HumaPen Savvio. India is an important market for us within the emerging markets. In an area like diabetes it is one of the largest markets with about 60 million patients. As a company our vision is to be among the top 20 companies in India by 2020, Olaizola said. The HumaPen Savvio will be priced at Rs 1,000 in the retail market. It will also be provided free of cost to physicians for distribution to patients. The pen will be co-promoted by the Lilly-Boehringer Ingelheim alliance in India. According to Olaiza, the USP of this product which he said resembled an accessory rather than a medical product is that it allows patients to manage the disease discreetly, besides being smaller and having a shelf-life of up to six years. He added that all the diabetes products launched worldwide will be brought to India also in the next few years. It is estimated that the number of diabetics in India will go up to 100 million in 15 years. From a market point of view we have been growing in double digits in the past 3-4 years. Lilly India has been growing faster than the market, he said. The company is also present in segments such as osteoporosis, cardiovascular, oncology and growth hormones. Continue reading >>

More in diabetes